Indivior Pharmaceuticals, Inc. (INDV), on Monday, announced that announced a $175 million accelerated share repurchase agreement with Barclays PLC (BARC.L,BCS) under its existing $400 million buyback program.
The final settlement is expected by the end of June.
The company said it will make an upfront payment of $175 million and expects to receive an initial delivery of approximately 3.72 million shares.
The final number of shares repurchased will be based on the volume-weighted average price during the term of the agreement.
The remaining $100 million under the share repurchase authorization may be used for additional buybacks.
The company said the agreement reflects confidence in its long-term strategy and does not impact its previously issued financial guidance.
In the pre-market trading, Indivior Pharmaceuticals is 3.27% higher at $38.89 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.